CBD Earned FDA Approval for Two Severe Childhood Epilepsy Syndromes
After decades of anecdotal evidence, high-quality randomized controlled trials led to FDA approval of purified CBD extract (Epidiolex) for Dravet and Lennox-Gastaut syndromes.
Quick Facts
What This Study Found
Early anecdotal evidence for cannabis as an anticonvulsant was recently replaced by high-quality data from randomized controlled studies. This led to FDA approval of purified CBD for two highly refractory pediatric epilepsy syndromes. About one-third of epilepsy patients are drug-resistant, defined as failure despite adequate trials of at least two appropriate medications.
Key Numbers
Approximately 50 million people worldwide have epilepsy. About one-third (roughly 17 million) are drug-resistant. FDA approved purified CBD for Dravet and Lennox-Gastaut syndromes.
How They Did This
Review of evidence from early anecdotal reports through modern randomized controlled trials supporting CBD as an anticonvulsant.
Why This Research Matters
The FDA approval of CBD for epilepsy represents a landmark moment - the first cannabis-derived prescription drug approved in the United States. It validates decades of patient advocacy and demonstrates that rigorous clinical trials can be conducted with cannabis compounds.
The Bigger Picture
The path from anecdotal cannabis-for-seizures evidence to FDA approval of a purified CBD product could serve as a model for how other cannabis-based medicines might gain regulatory acceptance through rigorous clinical trials.
What This Study Doesn't Tell Us
Short review focused on the approval pathway. Does not deeply analyze trial data or long-term outcomes. Approval was limited to two specific syndromes.
Questions This Raises
- ?Will CBD prove effective for other epilepsy types beyond Dravet and Lennox-Gastaut?
- ?Is purified CBD as effective as whole-plant extracts?
- ?What are the long-term effects of CBD use in children?
Trust & Context
- Key Stat:
- 50 million people worldwide have epilepsy; about one-third are drug-resistant and could benefit from new treatments like CBD.
- Evidence Grade:
- Strong - based on randomized controlled trials that led to FDA approval.
- Study Age:
- Published in 2018, the year Epidiolex received FDA approval.
- Original Title:
- Cannabidiol for Epilepsy: New Hope on the Horizon?
- Published In:
- Clinical therapeutics, 40(9), 1438-1441 (2018)
- Authors:
- Sanmartin, Paul E, Detyniecki, Kamil
- Database ID:
- RTHC-01824
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is CBD approved for epilepsy?
Yes. Purified CBD (Epidiolex) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy. This was the first cannabis-derived prescription drug approved in the US.
How many people with epilepsy don't respond to regular medications?
About one-third of epilepsy patients - roughly 17 million people worldwide - are drug-resistant, meaning seizures continue despite trying at least two appropriate medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01824APA
Sanmartin, Paul E; Detyniecki, Kamil. (2018). Cannabidiol for Epilepsy: New Hope on the Horizon?. Clinical therapeutics, 40(9), 1438-1441. https://doi.org/10.1016/j.clinthera.2018.07.020
MLA
Sanmartin, Paul E, et al. "Cannabidiol for Epilepsy: New Hope on the Horizon?." Clinical therapeutics, 2018. https://doi.org/10.1016/j.clinthera.2018.07.020
RethinkTHC
RethinkTHC Research Database. "Cannabidiol for Epilepsy: New Hope on the Horizon?" RTHC-01824. Retrieved from https://rethinkthc.com/research/sanmartin-2018-cannabidiol-for-epilepsy-new
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.